Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of obexelimab in relapsing multiple sclerosis
CTR20244579Phase 2Active
- Sponsor
- Zenas BioPharma
- Start
- Mar 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of obexelimab in multiple sclerosis (MS), sponsored by Zenas BioPharma. Started Mar 2025; status: active.
02
Drugs
obexelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20244579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244579.